Literature DB >> 9533478

Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.

P Russell1, S M Eley, M Green, A J Stagg, R R Taylor, M Nelson, R J Beedham, D L Bell, D Rogers, D Whittington, R W Titball.   

Abstract

The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy were assessed against experimental pneumonic plague infections induced by two strains of Yersinia pestis in a mouse model. When exposed to an aerosol of Y. pestis strain GB, containing 8.39 x 10(5) +/- 4.17 x 10(4) cfu, the retained dose was 7.3 x 10(3) +/- 2.3 x 10(3) cfu. When exposed to an aerosol of Y. pestis strain CO-92, containing 1.86 x 10(5) +/- 7.4 x 10(3) cfu, the retained dose was 3.4 x 10(4) +/- 2.6 x 10(3) cfu. Both strains resulted in a respiratory and systemic infection closely resembling human pneumonic plague. Ciprofloxacin prophylaxis and therapy was successful against both strains for up to 24 h after challenge, but not after 48 h. Both doxycycline prophylaxis and therapy regimens were ineffective against both strains, although strain CO-92 was more susceptible in vitro to doxycycline than strain GB and supra-MIC levels were achieved in the serum and lungs of the animal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533478     DOI: 10.1093/jac/41.2.301

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.

Authors:  David R Lonsway; Sandra K Urich; Henry S Heine; Sigrid K McAllister; Shailen N Banerjee; Martin E Schriefer; Jean B Patel
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

2.  In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.

Authors:  Jered M Wendte; Duraisamy Ponnusamy; Deanna Reiber; Jeffrey L Blair; Kenneth D Clinkenbeard
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

3.  Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Authors:  A Louie; H S Heine; B VanScoy; A Eichas; K Files; S Fikes; D L Brown; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

4.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

5.  New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Authors:  Jourdan A Andersson; Eric C Fitts; Michelle L Kirtley; Duraisamy Ponnusamy; Alex G Peniche; Sara M Dann; Vladimir L Motin; Sadhana Chauhan; Jason A Rosenzweig; Jian Sha; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Authors:  Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

7.  Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.

Authors:  Jourdan A Andersson; Jian Sha; Michelle L Kirtley; Emily Reyes; Eric C Fitts; Sara M Dann; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

Review 9.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

10.  Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.

Authors:  Nadine Lemaître; Isabelle Ricard; Elizabeth Pradel; Benoît Foligné; René Courcol; Michel Simonet; Florent Sebbane
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.